Concepedia

Robert L. Fine

RL

Statistics

Publications

95

Citations

7.4K

H-Index

49

Active since

1984

Affiliations

Columbia University(Current)

Columbia University Irving Medical Center

National Cancer Institute

Duke Medical Center

Duke University

Robert L. Fine is an author at Columbia University specializing in oncology, medicine, and pharmacology.

Publications per year

1984–2017

95

Publications

95

First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas

Jonathan Strosberg, Robert L. Fine, Junsung Choi et al. · Cancer · 2010 · 766 citations · Full text

, , +17

Safety and Survival With GVAX Pancreas Prime and <i>Listeria Monocytogenes</i>–Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer

Dung T. Le, Andrea Wang‐Gillam, Vincent J. Picozzi et al. · Journal of Clinical Oncology · 2015 · 600 citations

, , +17

Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: The Pancreas Center at Columbia University experience

Robert L. Fine, Anthony P. Gulati, Benjamin A. Krantz et al. · Cancer Chemotherapy and Pharmacology · 2013 · 257 citations

, , +16

Phorbol esters induce multidrug resistance in human breast cancer cells.

Robert L. Fine, Jitendra Patel, Bruce A. Chabner · Proceedings of the National Academy of Sciences · 1988 · 241 citations · Full text

, , +16

High-Dose Oral Tamoxifen, a Potential Multidrug-Resistance-Reversal Agent: Phase I Trial in Combination With Vinblastine

D L Trump, David C. Smith, Peter Ellis et al. · JNCI Journal of the National Cancer Institute · 1992 · 212 citations

, , +11

1–5 of 95